SoftBank Shares Surge as It Eyes Up to $30 Billion New Investment in OpenAI 
ASML’s EUV Monopoly Powers the Global AI Chip Boom 
First Abu Dhabi Bank Reports 22% Jump in Q4 Profit, Beats Market Expectations 
LVMH Investors Watch Earnings Closely as Luxury Recovery Faces New Challenges 
Toyota Retains Global Auto Sales Crown in 2025 With Record 11.3 Million Vehicles Sold 
Volkswagen CEO Oliver Blume Faces Crucial Year as Investors Demand Turnaround Results 
Meta Faces Lawsuit Over Alleged Approval of AI Chatbots Allowing Sexual Interactions With Minors 
Anthropic Raises 2026 Revenue Outlook by 20% but Delays Path to Profitability 
BYD and Exxon Mobil Strengthen Hybrid Technology Partnership 
Boeing Posts Fourth-Quarter Profit on Jeppesen Sale Despite Ongoing Unit Losses 
China Approves First Import Batch of Nvidia H200 AI Chips Amid Strategic Shift 
Woodside Energy Flags Lower 2026 Production Outlook Despite Strong Q4 Revenue Beat 
Google Halts UK YouTube TV Measurement Service After Legal Action 
Sam Altman Criticizes ICE Enforcement as Corporate Leaders Call for De-Escalation 
C3.ai in Merger Talks With Automation Anywhere as AI Software Industry Sees Consolidation 
Alibaba-Backed Moonshot AI Unveils Kimi K2.5 to Challenge China’s AI Rivals 
NEW YORK, May 22, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the U.S. District Court for the Southern District of New York on behalf of investors who purchased Neurotrope, Inc. ("Neurotrope") (NASDAQ:NTRP) securities between January 7, 2016, and April 28, 2017.
Click here to learn about the case: http://www.wongesq.com/pslra/neurotrope-inc?wire=3. There is no cost or obligation to you.
According to the complaint, throughout the class period, Neurotrope issued materially false and misleading statements and/or failed to disclose material information concerning the efficacy of its lead product candidate, Bryostatin-1. On May 1, 2017, Neurotrope issued a press release announcing “positive top-line results” of the pivotal Phase 2b trials of Bryostatin-1, noting “improvement in patients with moderate to severe Alzheimer’s disease.” However, the underlying trial data contradicts these representations, as the top-line data relating to the 20 microgram dose of Bryostatin-1 failed to produce results that were statistically significant. In addition, Neurotrope failed to disclose statements regarding the efficacy of the 40 microgram dose with regard to its primary and secondary endpoints. Upon this news, shares of Neurotrope fell from a close of $18.81 on April 28, 2017, to a close of $6.97 per share on May 1, 2017.
If you suffered a loss in Neurotrope you have until July 17, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/neurotrope-inc?wire=3.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
